BridgeBio Pharma, Inc. Overview
Pro stress-test →BridgeBio exists to develop transformative medicines for genetic conditions, addressing the fact that millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. The company combines commercial momentum with a robust late-stage pipeline positioned to drive significant growth through 2026 and beyond.
Strategic Profile
Pro stress-test →BridgeBio is advancing its commercial strategy for Attruby and aims to double its patient reach by 2026, reflecting the effectiveness of its decentralized model in driving meaningful healthcare solutions. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy.
Competitive Landscape
Pro stress-test →BridgeBio competes in genetic disease treatment space with 93 identified competitors including IVERIC bio and other biotechnology firms. As a rare disease-focused biopharmaceutical company with Attruby as its commercial anchor, BridgeBio differentiates through targeted genetic medicine development and emerging clinical proof-of-concept across multiple rare indications. Success will depend on execution against larger pharma players and specialized rare disease developers.
Industry Context
BridgeBio Pharma, Inc. operates in Biotechnology - Genetic Medicine & Rare Diseases.
Key facts
Founded: 2015 · Headquarters: Palo Alto, US · Revenue: $362.4M · Market cap: $15.2B